[go: up one dir, main page]

PE20050284A1 - Compuestos peptidicos como agonistas del receptor de melanocortina 4 (mc4) - Google Patents

Compuestos peptidicos como agonistas del receptor de melanocortina 4 (mc4)

Info

Publication number
PE20050284A1
PE20050284A1 PE2004000599A PE2004000599A PE20050284A1 PE 20050284 A1 PE20050284 A1 PE 20050284A1 PE 2004000599 A PE2004000599 A PE 2004000599A PE 2004000599 A PE2004000599 A PE 2004000599A PE 20050284 A1 PE20050284 A1 PE 20050284A1
Authority
PE
Peru
Prior art keywords
cys
arg
trp
phe
ala
Prior art date
Application number
PE2004000599A
Other languages
English (en)
Inventor
John Philip Mayer
David Lee Smiley
Mark Louis Heiman
David Benjamin Flora
Hansel Maxwell Hsiung
Lianshan Zhang
Jeanne L Hertel
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20050284A1 publication Critical patent/PE20050284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A COMPUESTOS PEPTIDICOS DE LA FORMULA I, INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE W ES Glu, Gln, Asp, Asn, Ala, Thr, Ser, Pro, ENTRE OTROS O ESTA AUSENTE; R1 ES H, C(O)CH3, C(O)(CH2)1-4CH3, C(O)(CH2)1-4NHC(NH)NH2, Tyr-bArg, ENTRE OTROS; m ES 1 o 2; n ES 1 a 4; R9 ES (CH2)p o (CH3)2C; p ES 1 o 2; R10 ES NH o ESTA AUSENTE; R7 ES UN HETEROARILO DE 5-6 MIEMBROS O UN ANILLO HETEROARILO DE 5-6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R4; R4 ES H, ALQUILO C1-C4 LINEAL O RAMIFICADO, FENILO, BENCILO, ENTRE OTROS; R8 ES FENILO, UN ANILLO FENILO OPCIONALMENTE SUSTITUIDO CON X o CICLOHEXILO; X ES H, Cl, F, Br, METILO o METOXI; R11 ES C(O) o CH2; R5 ES NH2, OH, GLICINOL, NH2-Pro-Ser, NH2-Pro-Lys, ENTRE OTROS; L ES S-S o S-CH2-S. SON COMPUESTOS PREFERIDOS: Ac-ciclo[Cys-His-D-Phe-Arg-Trp-Cys]-NH2; Ac-Cya-Arg-CICLO[Cys-His-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; Ac-Tyr-Arg-CICLO[Cys-Ala-His-D-Phe-Arg-Trp-Cys]-NH2; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON AGONISTAS DEL RECEPTOR MELANOCORTINA MC4 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS TALES COMO OBESIDAD, DIABETES MELLITUS Y DISFUNCION SEXUAL MASCULINA Y/O FEMENINA
PE2004000599A 2003-06-19 2004-06-18 Compuestos peptidicos como agonistas del receptor de melanocortina 4 (mc4) PE20050284A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47974003P 2003-06-19 2003-06-19
US55734704P 2004-03-29 2004-03-29
US57067604P 2004-05-13 2004-05-13
US57073704P 2004-05-13 2004-05-13

Publications (1)

Publication Number Publication Date
PE20050284A1 true PE20050284A1 (es) 2005-05-20

Family

ID=33556652

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000599A PE20050284A1 (es) 2003-06-19 2004-06-18 Compuestos peptidicos como agonistas del receptor de melanocortina 4 (mc4)

Country Status (17)

Country Link
US (1) US20070105759A1 (es)
EP (1) EP1644023A2 (es)
JP (1) JP2006527773A (es)
KR (1) KR20060014444A (es)
AR (1) AR044824A1 (es)
AU (1) AU2004251616A1 (es)
BR (1) BRPI0410731A (es)
CA (1) CA2530024A1 (es)
CR (1) CR8159A (es)
EA (1) EA200600055A1 (es)
EC (1) ECSP056236A (es)
IL (1) IL171931A0 (es)
MX (1) MXPA05013951A (es)
NO (1) NO20060259L (es)
PE (1) PE20050284A1 (es)
TW (1) TW200514791A (es)
WO (1) WO2005000339A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361294T1 (de) 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
EP1658273B1 (en) 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
EP3925614A3 (en) * 2005-07-08 2022-03-23 Ipsen Pharma Melanocortin receptor ligands
CA2614678A1 (en) * 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ligands of melanocortin receptors
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2555522T3 (es) 2007-11-05 2016-01-04 Ipsen Pharma S.A.S. Uso de melanocortinas para tratar la sensibilidad a la insulina
DK2554666T3 (en) 2008-01-02 2015-11-02 Danisco Us Inc PROCEDURE FOR OBTAINING ETHANOL WITHOUT glucoamylase USING PSEUDOMONAS saccharophila G4 amylase AND VARIATIONS THEREOF
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
CA2727317C (en) * 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
MX2012005859A (es) 2009-11-23 2012-12-17 Palatin Technologies Inc Peptidos lineales especificos del receptor de melanocortina-1.
EP2504352B1 (en) 2009-11-23 2018-11-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
SI3539551T1 (sl) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR101917854B1 (ko) * 2017-08-24 2018-11-12 한국콜마주식회사 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물
CN115010793A (zh) * 2022-06-17 2022-09-06 中国农业大学 玫瑰叶畸形病毒外壳蛋白多克隆抗体的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
GB9808229D0 (en) * 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
MXPA01005818A (es) * 1998-12-09 2003-07-21 Eleanor Rooseveltl Inst Composicion y metodo para la regulacion del peso del cuerpo y condiciones asociadas.
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
AU763510B2 (en) * 1999-03-29 2003-07-24 Procter & Gamble Company, The Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6659982B2 (en) * 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
HUP0303078A3 (en) * 2000-08-30 2012-02-28 Hoffmann La Roche Cyclic peptidies process for their preparation pharmaceutical compositions containing them and their use
WO2003006604A2 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
IL171931A0 (en) 2006-04-10
AR044824A1 (es) 2005-10-05
BRPI0410731A (pt) 2006-06-20
US20070105759A1 (en) 2007-05-10
ECSP056236A (es) 2006-04-19
AU2004251616A1 (en) 2005-01-06
TW200514791A (en) 2005-05-01
EP1644023A2 (en) 2006-04-12
MXPA05013951A (es) 2006-02-24
NO20060259L (no) 2006-03-14
WO2005000339A2 (en) 2005-01-06
CR8159A (es) 2006-02-09
CA2530024A1 (en) 2005-01-06
JP2006527773A (ja) 2006-12-07
WO2005000339A8 (en) 2005-04-21
EA200600055A1 (ru) 2006-08-25
WO2005000339A3 (en) 2005-02-03
KR20060014444A (ko) 2006-02-15

Similar Documents

Publication Publication Date Title
PE20050284A1 (es) Compuestos peptidicos como agonistas del receptor de melanocortina 4 (mc4)
PE20081878A1 (es) Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20141371A1 (es) Compuestos heterociclicos y usos de los mismos
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20020507A1 (es) Compuestos no-imidazoles como antagonistas del receptor histamina h3
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20050476A1 (es) Compuestos de pirrol y pirazol
NO20054185L (no) Methods of radiofluorination of biologically active vectors
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
DOP2003000765A (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease
NO20015428D0 (no) Anvendelse av selektive antagonister for den <alfa>1b- adrenerge reseptor for forbedring av seksuell dysfunksjon
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
BRPI0413676B8 (pt) compostos derivados de oxazol e oxadiazol e composições farmacêuticas úteis para a liberação oral de composto de peptídeo semelhante a glucagon-1 (glp-1) ou de peptídeo agonista de receptores de melatonina tipo 4 (mc4)
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
CL2011000533A1 (es) Compuestos derivados de isoquinolina sustituida; antagonista nk3; composicion farmaceutica que lo comprende; y uso en el tratamiento de enfermedades tales como psicosis, esquizofrenia, alzheimer, parkinson, entre otras.
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
AR063140A1 (es) Nuevo peptido de actinomadura nambiensis
PE20040906A1 (es) Derivados morfolinicos como agonistas de dopamina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal